Are you Dr. McLaughlin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 62 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
100 Haynes St
Second Floor
Manchester, CT 06040Phone+1 860-646-0670Fax+1 860-643-9388- Is this information wrong?
Summary
- Dr. Joseph McLaughlin, MD is an oncologist in Manchester, Connecticut. He is currently licensed to practice medicine in Connecticut, New York, and New Jersey. He is affiliated with Manchester Memorial Hospital and Yale-New Haven Hospital.
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2008 - 2011- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2008
Certifications & Licensure
NJ State Medical License 2021 - 2025
CT State Medical License 2011 - 2024
NY State Medical License 2022 - 2024
PA State Medical License 2008 - 2011- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 128 citationsQuantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancerJamaal Rehman, Gang Han, Daniel E. Carvajal-Hausdorf, Brad Wasserman, Vasiliki Pelekanou, Nikita Mani, Joseph McLaughlin, Kurt A. Schalper, David L. Rimm> ;Modern Pathology. 2017 Mar 1
- 126 citationsDifferential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung CancerKurt A. Schalper, Daniel E. Carvajal-Hausdorf, Joseph McLaughlin, Mehmet Altan, Vamsidhar Velcheti, Patricia Gaule, Miguel F. Sanmamed, Lieping Chen, Roy S. Herbst, Da...> ;Clinical Cancer Research. 2017 Jan 15
- 13 citationsEGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.Maria I. Toki, Daniel E. Carvajal-Hausdorf, Mehmet Altan, Joseph McLaughlin, Brian S. Henick, Kurt A. Schalper, Konstantinos N. Syrigos, David L. Rimm> ;Journal of Thoracic Oncology. 2016 Nov 1
- Join now to see all
Press Mentions
7 Hospitals Expanding Orthopedics Programs & Adding SurgeonsFebruary 13th, 2016
Hospital Affiliations
Yale-New Haven HospitalNew Haven, Connecticut- Manchester Memorial HospitalManchester, Connecticut
